FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2614-2621 June 21, 2007 Number 25 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Hirsch, M. S. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

SUMMARY

Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log₁₀ decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1–resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.

Source Information

From the Departments of Pharmacology and Molecular Sciences (M.A.M., L.S., S.X., S.B., C.R.C., J.O.L.) and Medicine (B.L.J., T.P.B., Y.Z., M.W.-R., R.H., R.F.S., C.L.T.), Johns Hopkins University School of Medicine; and the Howard Hughes Medical Institute (R.F.S.) — both in Baltimore; and the Division of Infectious Diseases, Naval Medical Center, San Diego, San Diego, CA (B.H.).

Address reprint requests to Dr. Thio at the Department of Medicine, Johns Hopkins University School of Medicine, 1503 E. Jefferson St., Baltimore, MD 21231, or at cthio{at}jhmi.edu.

Full Text of this Article

This article has been cited by other articles:

• Kawakami, T., Ooka, S., Mizoguchi, M., Soma, Y., Yamazaki, M. (2008). Remission of Hepatitis B Virus-Related Cryoglobulinemic Vasculitis with Entecavir. ANN INTERN MED 149: 911-912 [Full Text]  
• Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M. (2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 34218-34228 [Abstract] [Full Text]  
• McMahon, M. A., Siliciano, J. D., Lai, J., Liu, J. O., Stivers, J. T., Siliciano, R. F., Kohli, R. M. (2008). The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance Mutation. J. Biol. Chem. 283: 31289-31293 [Abstract] [Full Text]  
• Dienstag, J. L. (2008). Hepatitis B Virus Infection. NEJM 359: 1486-1500 [Full Text]  
• Hammer, S. M., Eron, J. J. Jr, Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., Jacobsen, D. M., Montaner, J. S. G., Richman, D. D., Yeni, P. G., Volberding, P. A. (2008). Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. JAMA 300: 555-570 [Abstract] [Full Text]  
• Zhu, M., Bifano, M., Xu, X., Wang, Y., LaCreta, F., Grasela, D., Pfister, M. (2008). Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients. Antimicrob. Agents Chemother. 52: 2836-2841 [Abstract] [Full Text]  
• Lin, P.-F., Nowicka-Sans, B., Terry, B., Zhang, S., Wang, C., Fan, L., Dicker, I., Gali, V., Higley, H., Parkin, N., Tenney, D., Krystal, M., Colonno, R. (2008). Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge. Antimicrob. Agents Chemother. 52: 1759-1767 [Abstract] [Full Text]  
• Domaoal, R. A., McMahon, M., Thio, C. L., Bailey, C. M., Tirado-Rives, J., Obikhod, A., Detorio, M., Rapp, K. L., Siliciano, R. F., Schinazi, R. F., Anderson, K. S. (2008). Pre-steady-state Kinetic Studies Establish Entecavir 5'-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 5452-5459 [Abstract] [Full Text]  
• (2007). More Details About Entecavir's Anti-HIV Effects. AIDS Clin Care 2007: 4-4 [Full Text]  
• Hirsch, M. S. (2007). Entecavir Surprise. NEJM 356: 2641-2643 [Full Text]  
• (2007). Caution Regarding Use of Entecavir in HIV/HBV Coinfected Patients. JWatch Infect. Diseases 2007: 1-1 [Full Text]